Rosetta Genomics' Q2 Net Loss Rises 62 Percent

Rosetta's loss rose sharply on increased SG&A spending and losses associated Parkway Clinical Labs, which the firm recently sold. It also announced plans for a cleantech division.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.